India Globalization Capital, Inc. (IGC)
| Market Cap | 31.52M |
| Revenue (ttm) | 532,000 |
| Net Income (ttm) | -16.01M |
| Shares Out | 52.53M |
| EPS (ttm) | -0.24 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 67,610 |
| Open | 0.610 |
| Previous Close | 0.612 |
| Day's Range | 0.571 - 0.620 |
| 52-Week Range | 0.420 - 1.790 |
| Beta | 3.71 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 9, 2022 |
About IGC
India Globalization Capital, Inc. purchases and resells physical infrastructure commodities. It operates through two segments, Infrastructure and Life Sciences. The company rents heavy construction equipment, including motor grader and rollers; and undertakes highway construction contracts. It also develops cannabinoid-based products and therapies, such as hemp-based tinctures to treat anxiety, and enhance the lifestyle of patients suffering from Alzheimer's under the Hyalolex brand name; CBD based tinctures, capsules, and topical analgesic cre... [Read more...]
Financial Performance
In 2021, IGC's revenue was $397,000, a decrease of -55.79% compared to the previous year's $898,000. Losses were -$15.02 million, 70.4% more than in 2020.
Financial StatementsNews
IGC Reports Financial Results for the Quarter Ended June 30, 2022
POTOMAC, Md.--(BUSINESS WIRE)-- #IGC--IGC announces its financial results for the three months ended June 30, 2022, which is the first quarter of the Company's 2023 fiscal year.
IGC Reports Financial Results for Fiscal Year Ended March 31, 2022
POTOMAC, Md.--(BUSINESS WIRE)-- #IGC--IGC Reports Financial Results for Fiscal Year Ended March 31, 2022.
IGC Acquires Exclusive Rights for a Potential Alzheimer's Drug Development Candidate
BETHESDA, Md.--(BUSINESS WIRE)-- #IGC--IGC is excited to announce that one of its subsidiaries reached an IP license agreement for a potential Alzheimer's drug development candidate.
IGC Receives U.S. Patent for Method and Composition for Treating Seizure Disorders
POTOMAC, Md.--(BUSINESS WIRE)-- #IGC--India Globalization Capital, Inc. (the “Company”) (NYSE American: IGC) announced today that the United States Patent and Trademark Office (“USPTO”) issued a patent ...
India Globalization Capital, Inc. (IGC) Announces Final Approval of Settlement of Shareholder Class Action Lawsuits
POTOMAC, Md.--(BUSINESS WIRE)--India Globalization Capital, Inc. (IGC) Announces Final Approval of Settlement of Shareholder Class Action Lawsuits.
India Globalization Capital Appoints Claudia Grimaldi to its Board of Directors
POTOMAC, Md.--(BUSINESS WIRE)-- #IGC--IGC's Board appointed Ms. Claudia Grimaldi as a non-independent Director on Mar 23'22. IGC has 5 directors including a majority who are independent
India Globalization Capital Posts Net Loss Of $2.38M For The Third Quarter
India Globalization Capital, Inc. IGC announced its financial results for the three months ending December 31, 2021 – quarter three of the company's 2022 fiscal year. Q3 Financial Highlights
IGC Reports Financial Results for the December 31, 2021 Quarter
POTOMAC, Md.--(BUSINESS WIRE)-- #IGC--IGC announces its financial results for the three months ending December 31, 2021 – quarter three of the Company's 2022 fiscal year.
The Rosen Law Firm, P.A. and Pomerantz LLP Announce Proposed Securities Class Action Settlement on Behalf of Purchase...
GREENBELT, Md., Jan. 31, 2022 /PRNewswire/ -- The Rosen Law Firm, P.A.
India Globalization Capital Appoints Former Congressman Jim Moran to Its Board of Directors
POTOMAC, Md.--(BUSINESS WIRE)-- #IGC--IGC Appoints Former Congressman Jim Moran to its Board of Directors.
Clinical Trial on Alzheimer's Patients Indicates Positive Safety and Tolerability Data for IGC's THC-Based Investigat...
POTOMAC, Md.--(BUSINESS WIRE)-- #IGC--Clinical Trial on Alzheimer's Patients Indicates Positive Safety and Tolerability Data for IGC's THC-Based Investigational New Drug
Phase 1 Clinical Trial Provides Valuable Insights on Safe and Effective Dosing of IGC-AD1 for Alzheimer's Patients
POTOMAC, MD,--(BUSINESS WIRE)-- #IGC--IGC-AD1 Phase 1 Clinical Trial Provides Valuable Insights on Safe and Effective Dosing of IGC-AD1 for Alzheimer's Patients.
Phase 1 Clinical Trial Data Indicate IGC's THC-based Investigational New Drug May Reduce Symptoms of Dementia in Alzh...
POTOMAC, Md.--(BUSINESS WIRE)-- #Alzheimers--IGC Phase 1 Clinical Trial Data Indicate IGC's THC-based Investigational New Drug May Reduce Symptoms of Dementia in Alzheimer's Patients.
IGC Posts Q2 Results, Reveals Promising Results From Clinical Trial Of THC-Drug For Alzheimer's Symptoms
India Globalization Capital, Inc. (AMEX: IGC) reported its financial results Friday for the three months ended September 30, 2021, with revenue of $56,000, compared to $125,000 in the same period of 202...
IGC Reports Financial Results for the September 30, 2021 Quarter
BETHESDA, Md.--(BUSINESS WIRE)-- #Alzheimers--IGC announces its financial results for the three months ended September 30, 2021, which is the second quarter of the Company's 2022 fiscal year.
IGC Announces Results of its 2021 Annual Stockholders Meeting
POTOMAC, Md.--(BUSINESS WIRE)-- #Alzheimers--Voting on all matters as disclosed on the Def Proxy filed with the SEC on Sep 15'21 were passed at IGC's Annual Meeting of Shareholders on Oct 15'21.
IGC Completes its Phase 1 Clinical Trial on Alzheimer's Patients, Reports Safety and Tolerability
POTOMAC, Md.--(BUSINESS WIRE)-- #Alzheimers--IGC Completes its Phase 1 Clinical Trial on Alzheimer's Patients, Reports Safety and Tolerability.
IGC Reports Financial Results for the June 30, 2021, Quarter
BETHESDA, Md.--(BUSINESS WIRE)-- #IGCAD1--IGC announces financial results for quarter ended Jun 30, 2021 & completion of Phase 1 clinical trial of IGC-AD1 to alleviate Alzheimer's symptoms.
An Unforgettable Week For Alzheimer's Treatment Stocks: Two Of Our Recent Top Names Spike On News Of Potentially Prom...
Screen capture via IGC's healthcare subsidiary Hyalolex. "Drops of Clarity" is their just-patented Alzheimer's treatment.
Why India Globalization Capital Shares Spiked Today
India Globalization Capital (AMEX:IGC) shares are trading higher after the company announced the issuance of a patent for the treatment of Alzheimer's disease using THC. The company was issued a patent...
India Globalization Capital Shares Skyrocket On Receiving Patent For THC Formula To Treat Alzheimer's Disease
India Globalization Capital, Inc. (AMEX: IGC) revealed Thursday that it has obtained a patent from the United States Patent and Trademark Office for the treatment of Alzheimer's disease. The patent (#11...
IGC Stock: The Huge Cannabis Patent News That Has IGC Flying High
IGC stock is moving up in a huge way today. The company is finally earning its patent for the treatment of Alzheimer's disease with cannabis.
IGC Announces Issuance of Patent for the Treatment of Alzheimer's Disease Using THC
POTOMAC, Md.--(BUSINESS WIRE)--IGC Announces Issuance of Patent for the Treatment of Alzheimer's Disease Using THC
IGC Completes the Final Cohort of Its Phase 1 Clinical Trial on Alzheimer's Patients
POTOMAC, Md.--(BUSINESS WIRE)-- #IGCAD1--IGC completed Final Cohort of Phase 1 clinical trial on its THC-based investigational new drug intended to alleviate symptoms of Alzheimer's disease.
IGC Reports Financial Results for the Fiscal Year Ended March 31, 2021
POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Reports Financial Results for the Fiscal Year Ended March 31, 2021.